BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed ONC catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:2da32381153fb21da13c@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:ONC P3 readout (est.): A Study to Evaluate Long-term Safety of Zanu
 brutinib Regimens in Participants With B-Cell Malignancies Who Participate
 d in BeiGene Parent Studies of Zanubrutinib
DESCRIPTION:A Study to Evaluate Long-term Safety of Zanubrutinib Regimens i
 n Participants With B-Cell Malignancies Who Participated in BeiGene Parent
  Studies of Zanubrutinib\nNCT04170283 | PHASE3 | ACTIVE_NOT_RECRUITING | s
 ponsor: BeOne Medicines\nPrimary completion date (ESTIMATED)\; top-line re
 sults usually follow later.\nTicker ONC (confidence 0.9)\nSource: https://
 clinicaltrials.gov/study/NCT04170283\nScheduling/reference data from publi
 c records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04170283
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:287ca78599c658cf0bce@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260513
DTEND;VALUE=DATE:20260514
SUMMARY:ONC APPROVAL: BEQALZI
DESCRIPTION:Approved 2026-05-13: BEQALZI (NDA220711 ORIG1)\nConfidence: con
 firmed\nTicker ONC (confidence 0.6)\nSource: https://www.accessdata.fda.go
 v/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220711\nSchedul
 ing/reference data from public records\; dates can move. Not investment\, 
 legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=220711
CATEGORIES:approval,confirmed
END:VEVENT
END:VCALENDAR
